Multiple Myeloma Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Multiple Myeloma Treatment Market Trends and it is Segmented by Drug Class (Immunomodulators, Proteasome Inhibitors, Monoclonal Antibodies, Histone Deacetylase (HDAC) Inhibitors, and Other Drug Classes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Values are Provided in Terms of USD Million for above segments

Multiple Myeloma Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Multiple Myeloma Industry Overview

The multiple myeloma market is fragmented and competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Karyopharm Therapeutic Inc., Sanofi S.A., Amgen Inc., Takeda Pharmaceutical Company, and Bristol-Myers Squibb Company, among other players.

Multiple Myeloma Market Leaders

  1. Bristol-Myers Squibb Company

  2. Takeda Pharmaceutical Company Limited

  3. Amgen Inc.

  4. Sanofi S.A.

  5. Karyopharm Therapeutics Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Multiple Myeloma Market - cl.png